Key result
LDL apheresis is a critical intervention for treating homozygous FH, heterozygous FH intolerant to conventional therapy, and patients with elevated Lp(a) or progressive cardiovascular disease.
LDL apheresis is highlighted as a critical intervention for managing high-risk patients with familial hypercholesterolemia or elevated Lp(a) who are intolerant or unresponsive to conventional medical therapy.
May inform refractory FH and Lp(a) management; leaves open need for randomized outcome trials.
Apheresis has an important role in the management of two common complex lipid disorders associated with a high risk of premature atherosclerotic disease, familial hypercholesterolemia (FH) and Lp(a) hyperlipidemia. More often than not, these high risk patients will first present to their primary care provider prior to consulting with a lipidologist. Because of this, FH and Lp(a)-hyperlipidemia require more emphasis globally in the public domain as well as in the medical community. Appropriate and aggressive treatment regimens include a combination of dietary and pharmacologic interventions with regularly scheduled apheresis sessions. LDL apheresis is a critical intervention for the successful treatment of homozygous FH patients, heterozygous FH patients intolerant to conventional therapy, patients with an elevated Lp(a) level or those patients with progressive cardiovascular disease despite maximum medical therapy. Newly released European guidelines emphasize the importance of screening and treatment of e...
No takes yet. Share an insight, caveat, or question.
Allian-Sauer et al. (2011) conducted a review in Familial hypercholesterolemia and elevated Lp(a) levels. Apheresis was evaluated. LDL apheresis is a critical intervention for treating homozygous FH, heterozygous FH intolerant to conventional therapy, and patients with elevated Lp(a) or progressive cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: